Wells Fargo Upgrades Travere Therapeutics to Overweight, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has upgraded Travere Therapeutics to Overweight and increased its price target from $9 to $27, indicating a positive outlook for the company's stock.
October 21, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal has upgraded Travere Therapeutics from Equal-Weight to Overweight and significantly raised the price target from $9 to $27, suggesting a strong positive outlook for the stock.
The upgrade from Equal-Weight to Overweight by a major financial institution like Wells Fargo, along with a substantial increase in the price target, indicates a strong positive sentiment towards Travere Therapeutics. This is likely to lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100